The pathogenesis and treatment of acid sphingomyelinase-deficient Niemann-Pick disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Schuchman, E H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acid sphingomyelinase; Lysosomal disorder; Niemann Pick disease

Indexed keywords

ENZYME INHIBITOR; SPHINGOMYELIN PHOSPHODIESTERASE;

ANIMAL; ENZYME REPLACEMENT; GENE THERAPY; GENETICS; HUMAN; MOUSE; MOUSE MUTANT; NIEMANN PICK DISEASE; REVIEW;

ANIMALS; ENZYME INHIBITORS; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HUMANS; MICE; MICE, KNOCKOUT; NIEMANN-PICK DISEASES; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 77649223760     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47048     Document Type: Conference Paper

References (69)

1. Barbon CM, Ziegler RJ, Li C, Armentano D, Cherry M, Desnick RJ et al. AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease. Mol Ther. 2005; 12: 431-440. (Pubitemid 41150128)
2. Cerneca F, Andolina M, Simeone R, Boscolo R, Ciana G, Bembi B. Treatment of patients with Niemann-Pick Type is using repeated amniotic epithelial cells implantation: correction of aggregation and coagulation abnormalities. Clin Pediatr. 1997; 36: 141-146. (Pubitemid 27131793)
3. Cox TM. Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr. 2005; 94 (Suppl 447): 69-75.
4. da Veiga Pereira L, Desnick RJ, Adler DA, Disteche CM, Schuchman EH. Regional assignment of the human acid sphingomyelinase gene (SMPD1) by PCR analysis of somatic cell hybrids and in situ hybridization to 11p15.1-p15.4. Genomics. 1991; 9: 229-234.
5. Daloze P, Delvin EE, Glorieux FH, Corman JL, Bettez P, Toussi T. Replacement therapy for inherited enzyme deficiency: liver orthotopic transplantation in Niemann-Pick disease Type A. Am J Med Genet. 1977; 1: 229-239.
6. Darroch PI, Dagan A, Granot T, He X, Gatt S, Schuchman EH. A lipid analogue that inhibits sphingomyelin hydrolysis and synthesis, increases ceramide, and leads to cell death. J Lipid Res. 2005; 46: 2315-2324. (Pubitemid 41532520)
7. DeMayo RF, Haims AH, McRae MC, Yang R, Mistry PK. Correlation of MRI-based bone marrow burden score with genotype and spleen status in Gaucher's disease. Am J Roentgenol. 2008; 191: 115-123. (Pubitemid 351955212)
8. Dhami R, Schuchman EH. Mannose 6-phosphate receptor- mediated uptake is defective in acid sphingomyelinase- deficient macrophages: implications for Niemann-Pick disease enzyme replacement therapy. J Biol Chem. 2004; 279: 1526-1532. (Pubitemid 38082682)
9. Dhami R, He X, Schuchman E. Gene expression analysis in acid sphingomyelinase deficient mice. Novel insights into disease pathogenesis and identification of potential biomarkers to monitor Niemann-Pick disease treatment. Mol Ther. 2005; 13: 556-563.
10. Dodge JC, Clarke J, Song A, Bu J, Yang W, Taksir TV et al. Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick Type A disease. Proc Natl Acad Sci USA. 2005; 102: 17822-17827. (Pubitemid 41803581)
11. Fan JQ. Acontradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol Sci. 2003; 24: 355-360.
12. Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999; 5: 112-115. (Pubitemid 29051008)
13. Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep. 2004; 5: 777-782.
14. Germain DP, Fan JQ. Pharmacological chaperone therapy by active-site specific chaperones in Fabry disease: in vitro and preclinical studies. Int J Clin Pharmacol Ther. 2009; 47 (Suppl 1): 111-117.
15. Gulbins E, Kolesnick R. Acid sphingomyelinase-derived ceramide signaling in apoptosis. Subcell Biochem. 2002; 36: 229-244.
16. Gulbins E, Kolesnick R. Raft ceramide in molecular medicine. Oncogene. 2003; 22: 7070-7077. (Pubitemid 37386676)
17. Gulbins E, Dreschers S,Wilker B, Grassme H. Ceramide, membrane rafts and infections. J Mol Med. 2004; 82: 357-363. (Pubitemid 38887865)
18. He X, Miranda SR, Xiong X, Dagan A, Gatt S, Schuchman EH. Characterization of human acid sphingomyelinase purified from the media of overexpressing Chinese hamster ovary cells. Biochim Biophys Acta. 1999; 1432: 251-264. (Pubitemid 29304533)
19. He X, Okino N, Dhami R, Dagan A, Gatt S, Schulze H et al. Purification and characterization of recombinant, human acid ceramidase. Catalytic reactions and interactions with acid sphingomyelinase. J Biol Chem. 2003; 278: 32978-32986. (Pubitemid 37055742)
20. Horinouchi K, Erlich S, Perl DP, Ferlinz K, Bisgaier CL, Sandhoff K et al. Acid sphingomyelinase deficient mice: a model of Types A and B Niemann-Pick disease. Nat Genet. 1995; 10: 288-293.
21. Jeyakumar M, Butters TD, Cortina-Borja M, Hunnam V, Proia RL, Perry VH et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA. 1999; 96: 6388-6393. (Pubitemid 29256675)
22. Jin HK, Schuchman EH. Combined bone marrow and intracerebral mesenchymal stem cell transplantation leads to synergistic visceral and neurological improvements in Niemann-Pick disease mice. Mol Ther. 2003; 26: 775-785.
23. Jones I, He X, Katouzian F, Darroch PI, Schuchman EH. Characterization of common SMPD1 mutations causing Types Aand B Niemann-Pick disease and generation of mutation-specific mouse models. Mol Genet Metab. 2008; 95: 152-162.
24. Kamoshita S, Aron AM, Suzuki K. Infantile Niemann- Pick disease. A chemical study with isolation and characterization of membranous cytoplasmic bodies and myelin. Am J Dis Child. 1969; 117: 379-394.
25. Kolesnick R, Fuks Z. Radiation and ceramide-induced apoptosis. Oncogene. 2003; 22: 5897-5906. (Pubitemid 37176710)
26. Kolesnick R, Kronke M. Regulation of ceramide production and apoptosis. Annu Rev Physiol. 1998; 60: 643- 665.
27. Kolzer M, Arenz C, Ferlinz K, Werth N, Schulze H, Klingenstein R et al. Phosphatidylinositol-3,5-bisphosphate is a potent and selective inhibitor of acid sphingomyelinase. Biol Chem. 2003; 384: 1293- 1298.
28. Kolzer M, Ferlinz K, Bartelsen O, Hoops SL, Lang F, Sandhoff K. Functional characterization of the postulated intramolecular sphingolipid activator protein domain of human acid sphingomyelinase. Biol Chem. 2004; 385: 1193-1195. (Pubitemid 40103794)
29. Lee CY, Krimbou L, Vincent J, Bernard C, Larramee P, Genest J Jr. et al. Compound heterozygosity at the sphingomyelin phosphodiesterase-1 (SMPD1) gene is associated with low HDL cholesterol. Hum Genet. 2003; 112: 552-562. (Pubitemid 36869049)
30. Levran O, Desnick RJ, Schuchman EH. Niemann-Pick disease: a frequent missense mutation in the acid sphingomyelinase gene of Ashkenazi Jewish Type A and B patients. Proc Natl Acad Sci USA. 1991a; 88: 3748-3752. (Pubitemid 21916701)
31. Levran O, Desnick RJ, Schuchman EH. Niemann-Pick Type B disease. Identification of a single codon deletion in the acid sphingomyelinase gene and genotype/ phenotype correlations in Type Aand B patients. J Clin Invest. 1991b; 88: 806-810.
32. Levran O, Desnick RJ, Schuchman EH. Identification and expression of a common missense mutation (L302P) in the acid sphingomyelinase gene of Ashkenazi Jewish Type A Niemann-Pick disease patients. Blood. 1992; 80: 2081-2087.
33. Levran O, Desnick RJ, Schuchman EH. Type A Niemann-Pick disease: a frameshift mutation in the acid sphingomyelinase gene (fsP330) occurs in Ashkenazi Jewish patients. Hum Mutat. 1993; 2: 317-319. (Pubitemid 23231510)
34. Lozano J, Morales A, Cremesti A, Fuks Z, Tilly JL, Schuchman E et al. Niemann-Pick disease versus acid sphingomyelinase deficiency. Cell Death Differ. 2001; 8: 100-103.
35. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999; 281: 249-254. (Pubitemid 29058114)
36. Mendelson DS, Wasserstein MP, Desnick RJ, Glass R, Simpson W, Skloot G et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006; 238: 339-345. (Pubitemid 43010612)
37. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell. 2007; 99: 129-140. (Pubitemid 46380925)
38. Mihaylova V, Hantke J, Sinigerska I, Cherninkova S, Raicheva M, Bouwer S et al. Highly variable neural involvement in sphingomyelinase-deficient Niemann- Pick disease caused by an ancestral Gypsy mutation. Brain. 2007; 130: 1050-1061. (Pubitemid 47355602)
39. Miranda SR, Erlich S, Friedrich VL Jr., Haskins ME, Gatt S, Schuchman EH. Biochemical, pathological, and clinical response to transplantation of normal bone marrow cells into acid sphingomyelinase-deficient mice. Transplantation. 1998; 65: 884-892. (Pubitemid 28201438)
40. Miranda SR, Erlich S, Friedrich VL Jr, Gatt S, Schuchman EH. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann-Pick disease. Gene Ther. 2000a; 7: 1768-1776.
41. Miranda SR, He X, Simonaro CM, Gatt S, Dagan A, Desnick RJ et al. Infusion of recombinant human acid sphingomyelinase into Niemann-Pick disease mice leads to visceral, but not neurological, correction of the pathophysiology. FASEB J. 2000b; 14: 1988-1995.
42. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med. 2000; 6: 1109-1114.
43. Mylla Neto G, Costa R, Fernandes PM, de Lima EC, Ribeiro FM, Stolf NA. Niemann-Pick disease in adult: report of a case surgically treated. Rev Hosp Clin Fac Med Sao Paulo. 1983; 38: 83-85.
44. Nicholson AG, Wells AU, Hooper J, Hansell DM, Kelleher A, Morgan C. Successful treatment of endogenous lipoid pneumonia due to Niemann-Pick Type B disease with whole-lung lavage.AmJ Respir Crit Care Med. 2002; 165: 128-131. (Pubitemid 34053369)
45. Otterbach B, Stoffel W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell. 1995; 81: 1053-1061.
46. Pavlu-Pereira H, Asfaw B, Poupctova H, Ledvinova J, Sikora J, Vanier MT et al. Acid sphingomyelinase deficiency. Phenotype variability with prevalence of intermediate phenotype in a series of twenty-five Czech and Slovak patients. Amulti-approach study. J Inherit Metab Dis. 2005; 28: 203-227. (Pubitemid 40723888)
47. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H et al. Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet. 2004; 12: 87-92. (Pubitemid 38263551)
48. Pittis MG, Ricci V, Guerci VI, Marcais C, Ciana G, Dardis A et al. Acid sphingomyelinase: identification of nine novel mutations among Italian Niemann Pick Type B patients and characterization of in vivo functional in-frame start codon.HumMutat. 2004; 24: 186-187.
49. Platt FM, Jeyakumar M. Substrate reduction therapy. Acta Paediatr. 2008; 97 (Suppl 457): 88-93. (Pubitemid 351421298)
50. Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 1997; 276: 428-431. (Pubitemid 27180707)
51. Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, vanWeely S et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999; 105: 151-156. (Pubitemid 29396979)
52. Qiu H, Edmunds T, Baker-Malcolm J, Karey KP, Estes S, Schwarz C et al. Activation of human acid sphingomyelinase through modification or deletion of C-terminal cysteine. J Biol Chem. 2003; 278: 32744- 32752.
53. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLoughlin M et al. Acid sphingomyelinase deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 1996; 86: 189- 199.
54. Scaggiante B, Pineschi A, Sustersich M, Andolina M, Agosti E, Romeo D. Successful therapy of Niemann- Pick disease by implantation of human amnioticmembrane. Transplantation. 1987; 44: 59-61.
55. 2+- stimulated sphingomyelinase is secreted bymany cell types and is a product of the acid sphingomyelinase gene. J Biol Chem. 1996; 271: 18431-18436.
56. Schuchman EH, Desnick RJ. Niemann-Pick disease Types A and B: acid sphingomyelinase deficiencies. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds). The metabolic and molecular bases of inherited diseases. 8th ed. New York: McGraw-Hill; 2001. p. 3589.
57. Schuchman EH, Miranda SR. Niemann-Pick disease: mutation update, genotype/phenotype correlations, and prospects for genetic testing. Genet Test. 1997; 1: 13-19. (Pubitemid 127526932)
58. Schuchman EH, Levran O, Suchi M, Desnick RJ. An MspI polymorphism in the human acid sphingomyelinase gene (SMPD1). Nucleic Acids Res. 1991a; 19: 3160.
59. Schuchman EH, Suchi M, Takahashi T, Sandhoff K, Desnick RJ. Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J Biol Chem. 1991b; 266: 8531-8539. (Pubitemid 21906542)
60. Schuchman EH, Levran O, Pereira LV, Desnick RJ. Structural organization and complete nucleotide sequence of the gene encoding human acid sphingomyelinase (SMPD1). Genomics. 1992; 12: 197-205.
61. Simonaro CM, Desnick RJ, McGovern MM, Wasserstein MP, Schuchman EH. The demographics and distribution of Type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet. 2002; 71: 1413-1419. (Pubitemid 36015894)
62. Simonaro CM, Park JH, Eliyahu E, Shtraizent N, McGovern MM, Schuchman EH. Imprinting at the SMPD1 locus: implications for acid sphingomyelinase- deficient Niemann-Pick disease. Am J Hum Genet. 2006; 78: 865-870.
63. Smanik EJ, Tavill AS, Jacobs GH, Schafer IA, Farquhar L, Weber FL Jr et al. Orthotopic liver transplantation in two adults with Niemann-Pick and Gaucher's diseases: implications for the treatment of inherited metabolic disease. Hepatology. 1993; 17: 42-49. (Pubitemid 23027382)
64. Vanier MT, Ferlinz K, Rousson R, Duthel S, Louisot P, Sandhoff K et al. Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease Type B patients from northern Africa. Hum Genet. 1993; 92: 325-330. (Pubitemid 23323591)
65. Victor S, Coulter JB, Besley GT, Ellis I, Desnick RJ, Schuchman EH et al. Niemann-Pick disease: sixteen- year follow-up of allogeneic bone marrow transplantation in a Type B variant. J Inherit Metab Dis. 2003; 26: 775-785. (Pubitemid 38139378)
66. Wan Q, Schuchman EH. A novel polymorphism in the human acid sphingomyelinase gene due to size variation of the signal peptide region. Biochim Biophys Acta. 1995; 1270: 207-210.
67. Wang N, Lv X, Su L, Zhao B, Zhang S, Miao J. D609 blocks cell survival and induces apoptosis in neural stem cells. Bioorg Med Chem Lett. 2006; 16: 4780- 4783.
68. Wasserstein MP, Aron A, Brodie SE, Simonaro C, Desnick RJ, McGovern MM. Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediatr. 2006; 149: 554-559. (Pubitemid 44441414)
69. Wolf C, Quinn PJ. Membrane lipid homeostasis. Subcell Biochem. 2004; 37: 317-357.